Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polygonum acre, also known as *Persicaria punctata* or dotted smartweed, is a botanical extract utilized for its phlebotonic, anti-inflammatory, and analgesic properties. It is primarily used in the management of vascular conditions, specifically hemorrhoidal disease and chronic venous insufficiency (CVI). The extract contains bioactive compounds such as flavonoids (including persicarin), tannins, and sesquiterpene dialdehydes like polygodial. These constituents are thought to improve venous tone, reduce capillary permeability, and inhibit inflammatory mediators. In clinical settings, particularly in South American phytotherapy, it is frequently formulated in combination with *Aesculus hippocastanum* (horse chestnut), *Smilax papyracea* (sarsaparilla), and rutin to treat symptoms of chronic venous disease, such as edema, pain, and varicose dilatation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polygonum acre.